Alternative propellant aerosol delivery systems

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 22, Issue 6, 2005, Pages 493-534

  Smyth, Hugh D C ^a   Leach, Chet L ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Asthma; Atomization; CFCs; COPD; Hydrofluoroalkanes; Metered dose inhaler

Indexed keywords

ALCOHOL; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ATROVENT HFA; BECLOMETASONE DIPROPIONATE; BITOLTEROL MESILATE; BRONCHODILATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CHLOROFLUOROCARBON 11; CORTICOSTEROID; CROMOGLYCATE DISODIUM; EXCIPIENT; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; HYDROFLUOROALKANE 227EA; INSULIN; IPRATROPIUM BROMIDE; LEVALBUTEROL; NEDOCROMIL SODIUM; NORFLURANE; PIRBUTEROL ACETATE; PROPELLANT; PROVENTIL HFA; SALBUTAMOL; SALBUTAMOL SULFATE; SOLUBILIZER; SOLVENT; SORBITAN TRIOLEATE; SURFACTANT; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XOPENEX HFA;

ADVERSE DRUG REACTION; AEROSOL; AREA UNDER THE CURVE; ASTHMA; BRONCHUS HYPERREACTIVITY; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYNAMICS; DYSPHONIA; EQUIPMENT DESIGN; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; GREENHOUSE GAS; HISTORY OF MEDICINE; HUMAN; HYDROPHILICITY; INFLAMMATION; MEDICAL NEBULIZER; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; METERED DOSE INHALER; MOLECULAR SIZE; NEBULIZATION; OZONE LAYER; PARTICLE SIZE; PLUME; REVIEW; SUSPENSION; VALVE;

EID: 33745200065     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v22.i6.10     Document Type: Review

References (156)

1. Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev 2003;55(7):807-28.
2. Purewal TS. Formulation of metered dose inhalers. In: Purewal TS, Grant DJW, editors. Metered dose inhaler technology. Buffalo Grove (IL): Interpharm; 1998.
3. Gupta A, Stein SW, Myrdal PB. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers. J Aerosol Med 2003;16(2):167-74.
4. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby R, Byron PR, Farr S, editors. Respiratory drug delivery V; 1996; Phoenix (AZ): Interpharm Press; 1996. p. 115-123.
5. Clark A. Pulmonary delivery technology: recent advantages and potential for the new millennium. In: Hickey A, editor. Pharmaceutical inhalation aerosol technology. 2 ed. New York: Marcel Dekker; 2004.
6. Leach C. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care. 2005;50(9):1228-52.
7. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethane: chlorine atom catalysed destruction of ozone. Nature 1974;274:810-2.
8. Lovelock JE. Natural halocarbons in the air and in the sea. Nature 1975;256:193-4.
9. Lovelock JE, Maggs RJ, Wade RJ. Halogenated hydrocarbons in and over the Atlantic. Nature 1973;241:194-6.
10. The stratosphere 1981, theory and measurements: WMO Global Ozone Research Monitoring Project; 1981. Report No.: Rep. No. 11.
11. Farman JC, Gardiner BG, Shanklin JD. Large losses of total ozone over Antarctica reveal serious ClOx/NOx interaction. Nature 1985;325:207-10.
12. Navarro RP. The Montreal Protocol and metered dose inhalers. Med Interface 1997;10(4):135-6.
13. D'Souza S. The Montreal Protocol and essential use exemptions. J Aerosol Med 1995;8 Suppl 1:S13-7.
14. Boulet LP. The ozone layer and metered dose inhalers. Can Respir J 1998;5(3):176-9.
15. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999;186(1):13-30.
16. Leach CL. Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol 1995;22(4):328.
17. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers - into the new millennium. Int J Pharm 2000;201(1):89-107.
18. Gupta PK, Adjei AL. Therapeutic inhalation aerosols. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997. p. 185-234.
19. Johnson KA. Preparation of peptide and protein powders for inhalation. Adv Drug Deliv Rev 1997;26:3-15.
20. Hickey AJ, Thompson D. Physiology of the airways. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 2004. p. 1-29.
21. Thompson D. Pharmacology of therapeutic aerosols. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 2004. p. 31-64.
22. Selam JL. Inhaled insulin for the treatment of diabetes: projects and devices. Exp Opin Pharmacother 2003;4(8):1373-7.
23. Cyr TD, Graham SJ, Li KY, Lovering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991;8(5):658-60.
24. Tansey I. Technology development of Airomir (salbutamol sulphate in CFC-free system). Br J Clin Practice 1995;(Suppl 9):13-5.
25. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 1999;186(1):3-12.
26. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med 1999;12(3):151-60.
27. Bleeker E. Clinical reality: the safety and efficacy of the world's first CFC-free MDI. Eur Respir Rev 1997;7(41):37-9.
28. Leach C. Preclinical safety of propellant HFA-134a and Airomir (salbutamol sulphate in CFC-free system). Br J Clin Practice 1995;(Suppl 9):10-12.
29. Meakin B, Lewis D, Ganderton D, Brambilla C. Countering challenges posed by mimicry of CFC performance using HFA systems. In: Byron PR, editor. RDD VII; 2000.
30. Dalby RN, Byron PR, Shepherd HR, Papadopoulos E. CFC propellant substitution: P-134a as a potential replacement for P-12 in MDIs. Pharm Technol 1990;14:26-33.
31. Gupta PK, Adjei AL. Non-ozone depleting propellants. In: Adjei AL, Gupta PK, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997. p. 591-623.
32. Byron PR, Miller NC, Blondino FE, Visich JE, Ward GH. Some aspect of alternative propellant solvency. In: Byron PR, editor. Respiratory drug delivery IV; 1994.
33. Blondino FE, Byron PR. Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants. Drug Dev Ind Pharm 1998;24(10):935-45.
34. Tzou T-Z. Density, excess molar volume, and vapor pressure of propellant mixtures in metered-dose inhalers: deviation from ideal mixtures. Respir Drug Deliv VI, Int. Symp., 6th 1998:439-43.
35. Smyth HDC, Mejia-Millan EA, Hickey AJ. The effect of ethanol on solvency vapor pressure, and emitted droplet size of solution metered dose inhalers containing HFA 134a. Respir Drug Deliv VIII 2002;2:735-8.
36. Lewis DA, Ganderton D, Meakin BJ, Brambilla G. Modulite: a simple solution to a difficult problem. Respiration 2005;72(Suppl 1):3-5.
37. Wright P. Polymers for the colloidal stabilization of drugs in HFAs. In: Byron PR, editor. RDD IV; 1994.
38. Smyth HDC, Beck VP, Williams D, Hickey AJ. The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon- free propellant-driven metered dose inhalers. AAPS PharmSciTech 2004;5(1):Article 7.
39. Smyth HDC, Hickey AJ. Comparative particle size analysis of solution propellant driven metered dose inhalers using cascade impaction and laser diffraction. Respir Drug Deliv VIII 2002;2:731-4.
40. Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated. Exp Opin Pharmacother 2004;5(5):1163-73.
41. Waugh J, Goa KL. Flunisolide HFA. Am J Respir Med 2002;1(5):369-72; discussion 373.
42. Myrdal PB, Karlage KL, Stein SW, Brown BA, Haynes A. Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. J Pharm Sci 2004;93(4):1054-61.
43. Ganderton D, Lewis D, Davies R, Meakin B, Church T. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler. Respir Med 2003;97 (Suppl D):S4-9.
44. Rogueda P. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Exp Opin Drug Deliv 2005;2(4):625-38.
45. Michael Y, Chowdhry BZ, Ashurst IC, Snowden MJ, Davies-Cutting C, Gray S. The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments. Int J Pharm 2000;200(2):279-88.
46. Blondino FE, Byron PR. Drug stability in non-aqueous solutions - influence of surfactant concentration. Respir Drug Deliv V, Program Proc., Int. Symp., 5th 1996:125-31.
47. Wyatt DA, Vincent B. Electrical effects in non-aqueous systems. J Biopharm Sci 1992;3(1-2):27-31.
48. Johnson KA. Interfacial phenomena and phase behavior in metered-dose inhaler formulations. In: Hickey AJ, editor. Inhalation aerosols. New York: Marcel Dekker; 1996. p. 385-415.
49. Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) suspensions. Int J Pharm 2004;284(1-2):75-82.
50. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a. Pharm Res 2004;21(9):1607-14.
51. Berry J, Kline LC, Sherwood JK, Chaudhry S, Obenauer-Kutner L, Hart JL, et al. Influence of the size of micronized active pharmaceutical ingredient on the aerodynamic particle size and stability of a metered dose inhaler. Drug Dev Ind Pharm 2004;30(7):705-14.
52. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000;17(2):168-74.
53. Weers JG, Clark AR, Challoner P. High dose inhaled powder delivery: challanges and techniques. In: Dalby RN, Byron PR, Peart J, Farr SJ, editors. Respiratory Drug Delivery IX; 2004; Desert Springs, CA, USA: DHI; 2004.
54. Kotsokechagia T, Smith A, Miller NC, Radspinner D. The relationship between fine particle mass and drug concentration for high powder loading pressurized metered dose inhalers. In: Proceedings of 13th Meeting of the Aerosol Society: Drug Delivery to the Lungs XIII.; 2002; London, UK; 2002.
55. Schultz RK, Dupont RL, Ledoux KA. Issues surrounding metered dose valve technology: past, present, and future perspectives. In: Byron PR, editor. RDD IV; 1994.
56. Tiwari D, Goldman D, Dixit S, Malick WA, Madan PL. Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant. Drug Dev Ind Pharm 1998;24(4):345-52.
57. FDA. Guidance for industry metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. CDERGUID|2180dft.wpd, Nov 1998, http://www.fda.gov/cder/guidance/2180dft.pdf;
58. Howlett D, Colwell J, Goldsmith S, McCallion ON. Correlation of extractables and leachables from marketed pMDIs. In: Byron PR, editor. Respiratory drug delivery VIII; 2002.
59. Crowder TM, Louey MD, Sethuraman VV, Smyth HDC, Hickey AJ. 2001: an odyssey in formulation and design. Pharm Technol 2001;25(7):99-113.
60. Smyth HDC. Propellant-driven metered dose inhalers for pulmonary drug delivery. Exp Opin Drug Deliv 2004;2(1):53-74.
61. Dunbar CA. Atomization mechanisms of the pressurized metered dose inhaler. Part Sci Technol 1998;15(3-4):253-71.
62. Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs. Respir Drug Delivery V, Program Proc., Int. Symp., 5th 1996:133-44.
63. Corren J, Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther 2003;25(3):776-98.
64. Barry PW, O'Callaghan C. The influence of inhaler selection on efficacy of asthma therapies. Adv Drug Deliv Rev 2003;55(7):879-923.
65. Dubus JC, Rhem R, Dolovich M. Delivery of HFA and CFC salbutamol from spacer devices used in infancy. Int J Pharm 2001;222(1):101-8.
66. Williams RO 3rd, Patel AM, Barron MK, Rogers TL. Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. Drug Dev Ind Pharm 2001;27(5):401-12.
67. Ahrens R, Lux C, Bahl T, Han SH. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol 1995;96(2):288-94.
68. Jenkins M. Clinical evaluation of CFC-free metered dose inhalers. J Aerosol Med 1995;8 (Suppl 1):S41-7.
69. Kleerup EC, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109(3):702-7.
70. Dahl R, Ringdal N, Ward SM, Stampone P, Donnell D. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate. Br J Clin Pract 1997;51(1):11-5.
71. Dockhorn RJ, Wagner DE, Burgess GL, Hafner KB, Letourneau K, Colice GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Ann Allergy Asthma Immunol 1997;79(1):85-8.
72. Maesen FP, Greefhorst LP, Smeets JJ, Wald FD, Cornelissen PJ. Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma. Respiration 1997;64(4):273-80.
73. Nogami-Itoh M, Yakuo I, Hammerbeck DM, Miller RL, Takeyama K. The equivalent bronchodilator effects of salbutamol formulated in chlorofluorocarbon and hydrofluoroalkane-134a metered dose inhalers on the histamine-induced pulmonary response in dogs. Pharm Res 1997;14(2):208-12.
74. Blumenthal MN, Casale TB, Fink JN, Uryniak T, Casty FE. Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial. J Allergy Clin Immunol 1998;101(1 Pt 1):7-13.
75. Davies RJ, Stampone P, O'Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998;92 Suppl A:23-31.
76. Hermann R, Ruus P, Schneider E, de Mey C. Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate. Arzneimittelforschung 1998;48(6):663-7.
77. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12(6):1346-53.
78. Ramsdell JW, Colice GL, Ekholm BP, Klinger NM. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ann Allergy Asthma Immunol 1998;81(6):593-9.
79. Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998;92 Suppl A:9-15.
80. Thompson PJ, Davies RJ, Young WF, Grossman AB, Donnell D. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 1998;92 Suppl A:33-9.
81. Ayres JG, Simmons JL, Stampone P. Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients. Respir Med 1999;93(1):27-32.
82. Bronsky E, Ekholm BP, Klinger NM, Colice GL. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. J Asthma 1999;36(1):107-14.
83. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104(6):1215-22.
84. Colice GL, Klinger NM, Ekholm BP, Dockhorn RJ. Proventil HFA prevents exercise-induced bronchoconstriction in children. J Asthma 1999;36(8):671-6.
85. Demedts M, Cohen R, Hawkinson R. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract 1999;53(5):331-8.
86. Furukawa C, Atkinson D, Forster TJ, Nazzario K, Simpson B, Uryniak T, et al. Controlled trial of two formulations of cromolyn sodium in the treatment of asthmatic patients > or = 12 years of age. Intl Study Group. Chest 1999;116(1):65-72.
87. Goldin JG, Tashkin DP, Kleerup EC, Greaser LE, Haywood UM, Sayre JW, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999;104(6):S258-67.
88. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane- 134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999;115(2):343-51.
89. Harrison LI, Soria I, Cline AC, Ekholm BP. Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol 1999;51(11):1235-40.
90. Jacobson K, Chervinsky P, Noonan M, Kane RE, Banerji D, Uryniak T. Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. Ann Allergy Asthma Immunol 1999;83(4):327-33.
91. Juniper EF, Buist AS. Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group. Chest 1999;116(5):1297-303.
92. Milanowski J, Qualtrough J, Perrin VL. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Respir Med 1999;93(4):245-51.
93. Parameswaran KN, Inman MD, Ekholm BP, Morris MM, Summers E, O'Byrne PM, et al. Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am J Respir Crit Care Med 1999;160(1):354-7.
94. Ramsdell JW, Klinger NM, Ekholm BP, Colice GL. Safety of long-term treatment with HFA albuterol. Chest 1999;115(4):945-51.
95. Ayres JG, Millar AB, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. UK study group. Respir Med 2000;94 Suppl B:S42-50.
96. Bateman ED, Adler L, Chyrek-Borowska S, Thenman K, Banerji D, et al. Inhaled triamcinolone acetonide HFA 450 mcg twice daily compared with beclomethasone dipropionate CFC 500 mcg twice daily in adults with moderate persistent asthma. Clin Drug Invest 2000;20:9-17.
97. Baumgarten CR, Dorow P, Weber HH, Gebhardt R, Kettner J, Sykes AP. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group. Respir Med 2000;94 (Suppl B): S17-21.
98. Boccuzzi SJ, Wogen J, Roehm JB. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Clin Ther 2000;22(2):237-47.
99. Farmer IS, Middle M, Savic J, Perri VL, Herdman MJ. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma. Respir Med 2000;94(1):57-63.
100. Goldberg J, Bohning W, Schmidt P, Freund E. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison. Respir Med 2000;94(10):948-53.
101. Huchon G, Hofbauer P, Cannizzaro G, Iacono P, Wald F. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J 2000;15(4):663-9.
102. Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000;94 Suppl B:S10-6.
103. Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin Pharmacokinet 2000;39(Suppl 1):17-22.
104. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 2000;94(6):549-55.
105. Nelson HS, Kane RE, Petillo J, Banerji D. Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. Azmacort HFA Study Group. J Asthma 2000;37(2):145-52.
106. Perruchoud AP, Lundback B, Yigla M, Sykes AP. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Respir Med 2000;94 Suppl B:S35-41.
107. Shapiro G, Bronsky E, Murray A, Barnhart F, VanderMeer A, Reisner C. Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch Pediatr Adolesc Med 2000;154(12):1219-25.
108. Tonnel AB, Bons J, Legendre M, Prud'Homme A, Bugnas B, Evano-Celli I, et al. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Respir Med 2000;94 Suppl B:S29-34.
109. Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma. Respir Med 2001;95(3):212-20.
110. Casale TB, Nelson HS, Corren J, Newman K. Long-term safety of flunisolide hydrofluoroalkane metered-dose inhaler in adults and adolescents with asthma. Clin Drug Invest 2001;21:755-764.
111. Fireman P, Prenner BM, Vincken W, Demedts M, Mol SJ, Cohen RM. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann Allergy Asthma Immunol 2001;86(5):557-65.
112. Lumry W, Noveck R, Weinstein S, Barnhart F, Vandermeer A, Murray A, et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Allergy Asthma Immunol 2001;86(3):297-303.
113. Nolting A, Sista S, Abramowitz W. Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 2001;22(9):373-82.
114. Taylor J, Kotch A, Rice K, Ghafouri M, Kurland CL, Fagan NM, et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest 2001;120(4):1253-61.
115. Worth H, Muir JF, Pieters WR. Comparison of hydrofluoroalkane- beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration 2001;68(5):517-26.
116. Anderson PB, Langley SJ, Mooney P, Jones J, Addlestone R, Rossetti A, et al. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics. J Investig Allergol Clin Immunol 2002;12(2):107-13.
117. Bousquet J, Cantini L. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite). Respir Med 2002;96 (Suppl D):S17-27.
118. Fowler SJ, Orr LC, Sims EJ, Wilson AM, Currie GP, McFarlane L, et al. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest 2002;122(2):618-23.
119. Hawksworth RJ, Sykes AP, Faris M, Mant T, Lee TH. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2002;88(5):473-7.
120. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002;121(6):1824-32.
121. Langley SJ, Sykes AP, Batty EP, Masterson CM, Woodcock A. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann Allergy Asthma Immunol 2002;88(5):488-93.
122. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002;122(2):510-6.
123. Nolting A, Sista S, Abramowitz W. Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J Pharm Sci 2002;91(2):424-32.
124. Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics 2002;20(10):653-64.
125. Szefler SJ, Warner J, Staab D, Wahn U, Le Bourgeois M, van Essen-Zandvliet EE, et al. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open-label, randomized trial. J Allergy Clin Immunol 2002;110(1):45-50.
126. Joguparthi V, Breen P, Compadre C, Zhou X, Gann L, Hiller FC, et al. Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. J Aerosol Med 2003;16(1):47-53.
127. Brazinsky SA, Lapidus RJ, Weiss LA, Ghafouri M, Fagan NM, Witek TJ. One-year evaluation of the safety and efficacy of ipratropium bromide HFA and CFC inhalation aerosols in patients with chronic obstructive pulmonary disease. Clin Drug Invest 2003;23(3):181-91.
128. Grzelewska-Rzymowska I, Malolepszy J, de Molina M, Sladek K, Zarkovice J, Siergiejko Z. Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses. Respir Med2003;97(Suppl D):S10-9.
129. Lyttle B, Gilles J, Panov M, Emeryk A, Wixon C. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children. Can Respir J 2003;10(2):103-9.
130. Holz O, Zuhlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004;17(4):233-8.
131. Jeffrey P. Structural alterations and inflammation of bronchi in asthma. Int J Clin Practice 1998(Suppl 96):5-14.
132. Howarth PH. Small airways and asthma. An important therapeutic target? Am J Respir Crit Care Med 1998;157(5 Pt 2):S173.
133. Kraft M, Djukanovic R, Wilson S. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154(1505-10).
134. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104(6):1215-22.
135. Gross G, Cohen RM, Guy H. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. J Asthma 2003;40(5):487-95.
136. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 2000;94(6):549-55.
137. 99m-labelled QVAR delivered using an Autohaler device in children. Eur Respir J 2003;21(6):1007-11.
138. Conway JH, Walker P, Perkins G. Lung deposition characteristics of HFA-134a beclomethasone dipropionate delivered via an autohaler. Eur Respir J 1999;14(Suppl 30):196s.
139. Leach C, Davidson PJ, Hasselquist BE, Boudreau RJ. The influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005.
140. Leach CL, Bethke TD, Boudreau RJ, Hasselquist BE, Drollman A, Davidson P, et al. 2-D and 3-D imaging show ciclesonide has high lung deposition and peripheral deposition: a nonrandomized study in healthy volunteers. J Aerosol Med 2005. (In press.)
141. Chrousos GP, Ghaly L, Shedden A, lezzoni DG, Harris AG. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005;128(1):70-7.
142. Langley SJ, Houghton CM, Singh SD. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients. Respiration 2005;72 (Suppl 1):35-7.
143. Molimard M, Guenole E, Duvauchelle T, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration 2005;72 (Suppl 1):28-34.
144. Dusser D, Vicaut E, Lefrancois G. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Respiration 2005;72 Suppl 1:20-7.
145. Bousquet J, Guenole E, Duvauchelle T, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration 2005;72 (Suppl 1):13-9.
146. Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004;58(4):359-66.
147. Hartung TK, Allbutt H, Dewar M, Innes JA, Crompton GK. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think? Respiration 2002;69(4):314-9.
148. Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5(26):1-149.
149. Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrancois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 2005;72 (Suppl 1):6-12.
150. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ 2001;323(7318):896-900.
151. Ram FS. Clinical efficacy of inhaler devices containing beta(2)-agonist bronchodilators in the treatment of asthma: cochrane systematic review and meta-analysis of more than 100 randomized, controlled trials. Am J Respir Med 2003;2(4):349-65.
152. Ram FS, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002(1): CD002170.
153. Lipworth BJ, Sims EJ,Taylor K, Cockburn W, Fishman R. Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. Br J Clin Pharmacol 2005;59(1):5-13.
154. Anonymous. NICE endorses costly inhaler devices for children if asthma better controlled. Pharm J 2002;268(7194):521-527.
155. Sesti AM, Armitstead JA, Hall KN, Jang R, Milne S. Cost-minimization analysis of hand held nebulizer vs metered dose inhaler protocol for management of acute asthma exacerbations in the emergency department. ASHP Midyear Clinical Meeting 1997;32:MCS-7.
156. Forte R Jr, Dibble C. The role of international environmental agreements in metered-dose inhaler technology changes. J Allergy Clin Immunol 1999;104(6):S217-20.